Work

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

Year: 2013

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet

DOI: 10.1016/s0140-6736(13)61751-1

Authors: Josef S Smolen, Paul Emery, Roy Fleischmann, Ronald F van Vollenhoven, Karel Pavelka, Patrick Durez, Benoît Guérette, Hartmut Kupper, Laura Redden, Vipin Arora, Arthur Kavanaugh

Institutions: Klinik Hietzing, Medical University of Vienna, University of Leeds, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust, NIHR Leeds Musculoskeletal Biomedical Research Unit, The University of Texas Southwestern Medical Center, Karolinska University Hospital, Charles University, Cliniques Universitaires Saint-Luc, UCLouvain, AbbVie (United States), AbbVie (Germany), University of California San Diego

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: AbbVie, National Institute for Health and Care Research, Versus Arthritis

Awards: NIHR Senior Investigator Award, G8903934815

OpenAlex ID: W2168751860

FWCI: 23.1

Cites: 43

Cited by: 285

Related to: 10